The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Targeted therapies in breast cancer: New challenges to fight against resistance
Open accessAbstract
Breast cancer is the most common type of cancer found in women and today represents a significant challenge to public health. With the latest breakthroughs in molecular biology and immunotherapy, very specific targeted therapies have been tailored to the specific pathophysiology of different types of breast cancers. These recent developments have contributed to a more efficient and specific treatment protocol in breast cancer patients. However, the main challenge to be further investigated still remains the emergence of therapeutic resistance mechanisms, which develop soon after the onset of therapy and need urgent attention and further elucidation. What are the recent emerging molecular resistance mechanisms in breast cancer targeted therapy and what are the best strategies to apply in order to circumvent this important obstacle? The main scope of this review is to provide a thorough update of recent developments in the field and discuss future prospects for preventing resistance mechanisms in the quest to increase overall survival of patients suffering from the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Formisano, L., Nappi, L., Rosa, R., Marciano, R., D’Amato, C., D’Amato, V., Damiano, V., Raimondo, L., Iommelli, F., Scorziello, A., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3650 · Cited by 73
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3845 · Cited by 953
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
The ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608
Triple-negative breast cancer: epidemiological considerations and recommendations
Boyle, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds187 · Cited by 593
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
Targeting Mitosis in Cancer: Emerging Strategies
Dominguez-Brauer, C., Thu, K. L., Mason, J. M., Blaser, H., Bray, M. R., & Mak, T. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.006 · Cited by 495
Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis
Ranpura, V., Hapani, S., & Wu, S. (2011) · JAMA · doi:10.1001/jama.2011.51 · Cited by 428
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 369
Banerjee, S., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 357
Linderholm, B. K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., & Lewensohn, R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp062 · Cited by 347
Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Gonzalez-Angulo, A. M., Krop, I., Levinson, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0948 · Cited by 343
Triple negative breast cancer: unmet medical needs
Pal, S. K., Childs, B. H., & Pegram, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1293-1 · Cited by 322
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
PI3K/Akt/mTOR inhibitors in breast cancer.
Lee, J. J. X., Loh, K. W.-J., & Yap, Y. S. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0089 · Cited by 276
Targeting HER2 for the Treatment of Breast Cancer
Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
Neuropilins in neoplasms: Expression, regulation, and function
Bielenberg, D. R., Pettaway, C. A., Takashima, S., & Klagsbrun, M. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.024 · Cited by 255
Gianni, L., Romieu, G. H., Lichinitser, M., Serrano, S. V., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, A., Lipatov, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7912 · Cited by 254
Barok, M., Tanner, M., Köninki, K., & Isola, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2868 · Cited by 226
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00385 · Cited by 224
Trastuzumab in the Treatment of Breast Cancer
Maximiano, S., Magalhães, P., Guerreiro, M. P., & Morgado, M. (2016) · BioDrugs · doi:10.1007/s40259-016-0162-9 · Cited by 223
Rojo, F., Najera, L., Lirola, J., Jiménez, J., Guzmán, M., Sabadell, M. D., Baselga, J., & Cajal, S. R. Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1560 · Cited by 205
Therapeutic targets of triple‐negative breast cancer: a review
Jamdade, V. S., Sethi, N., Mundhe, N. A., Kumar, P., Lahkar, M., & Sinha, N. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13211 · Cited by 205
Brennan, S. E., Kuwano, Y., Alkharouf, N., Blackshear, P. J., Gorospe, M., & Wilson, G. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4238 · Cited by 205
HER2-directed therapy: current treatment options for HER2-positive breast cancer
Ahmed, S., Sami, A., & Xiang, J. (2015) · Breast Cancer · doi:10.1007/s12282-015-0587-x · Cited by 185
PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn, Jx, Lee, Kiley, Loh, K. W.-J., Yoon-Sim, & Yap (2015) · 癌症生物学与医学:英文版 · Cited by 185
Fox, S. B., Generali, D. G., & Harris, A. L. (2007) · Breast Cancer Research · doi:10.1186/bcr1796 · Cited by 182
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Ma, J., Lyu, H., Huang, J., & Liu, B. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-105 · Cited by 180
How Does Multistep Tumorigenesis Really Proceed?
Chaffer, C. L., & Weinberg, R. A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0788 · Cited by 179
Garrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 178
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2 -Amplified Gastric Cancer Cells
Chen, C.-T., Kim, H., Liska, D., Gao, S., Christensen, J. G., & Weiser, M. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0754 · Cited by 178
Targeted Therapy for Breast Cancer Prevention
den Hollander, P., Savage, M. I., & Brown, P. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00250 · Cited by 177
Fan, W., Chang, J., & Fu, P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.93 · Cited by 174
Mechanisms of lapatinib resistance in HER2-driven breast cancer
D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., & Bianco, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.08.001 · Cited by 164
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
Mechanisms of resistance to anti-angiogenesis therapies
Giuliano, S., & Pagès, G. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.002 · Cited by 158
Self-citationTherapeutic Targeting of Integrin αvβ6 in Breast Cancer
Moore, K. M., Thomas, G. J., Duffy, S. W., Warwick, J., Gabe, R., Chou, P., Ellis, I. O., Green, A. R., Haider, S. A., Brouilette, K., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju169 · Cited by 148
HER-2 Positive Breast Cancer - a Mini-Review
Asif, H. M., Sultana, S., Ahmed, S., Akhtar, N., & Tariq, M. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.4.1609 · Cited by 146
The Evolving Landscape of HER2 Targeting in Breast Cancer
Moasser, M. M., & Krop, I. E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2286 · Cited by 144
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies
Murphy, C. G., & Dickler, M. N. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0121 · Cited by 141
Mittendorf, E. A., Vila, J., Tucker, S. L., Chávez‐MacGregor, M., Smith, B. D., Symmans, W. F., Şahin, A. A., Hortobágyi, G. N., & Hunt, K. K. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6478 · Cited by 139
Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity
Ramsay, A. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12380 · Cited by 138
Ni, J., Ramkissoon, S. H., Xie, S., Goel, S., Stover, D. G., Guo, H., Luu, V., Marco, E., Ramkissoon, L. A., Kang, Y. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4120 · Cited by 136
Denduluri, N., Somerfield, M. R., Eisen, A. F., Holloway, J. N., Hurria, A., King, T. A., Lyman, G. H., Partridge, A. H., Telli, M. L., Trudeau, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.0182 · Cited by 134
Ye, X., Zhu, H., Bai, W., Wang, T., Wang, L., Chen, Y., Yang, A., & Jia, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-134 · Cited by 133
The therapeutic potential of mTOR inhibitors in breast cancer
Steelman, L. S., Martelli, A. M., Cocco, L., Libra, M., Nicoletti, F., Abrams, S. L., & McCubrey, J. A. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12958 · Cited by 124
Use of molecular markers for predicting therapy response in cancer patients
Duffy, M. J., O’Donovan, N., & Crown, J. P. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.004 · Cited by 123
Beauclair, S., Formento, P., Fischel, J., Lescaut, W., Largillier, R., Chamorey, E., Hofman, P. M., Ferrero, J.-M., Pagès, G., & Milano, G. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm181 · Cited by 121
Self-citationGiuliano, M., Hu, H., Wang, Y.-C., Fu, X., Nardone, A., Herrera, S., Mao, S., Contreras, A., Gutiérrez, C., Wang, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2728 · Cited by 118
Mole, D. R., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · IUBMB Life · doi:10.1080/15216540252774757 · Cited by 117
Duong, M. N., Cleret, A., Matera, E., Chettab, K., Mathé, D., Valsesia‐Wittmann, S., Clemenceau, B., & Dumontet, C. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0569-0 · Cited by 117
Mittendorf, E. A., Ardavanis, A. S., Symanowski, J. T., Murray, J. L., Shumway, N. M., Litton, J. K., Hale, D. F., Perez, S. A., Anastasopoulou, E. A., Pistamaltzian, N. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw150 · Cited by 113
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Wilks, S. T. (2015) · The Breast · doi:10.1016/j.breast.2015.06.002 · Cited by 101
Targeted Therapies in Triple-Negative Breast Cancer
Marmé, F., & Schneeweiß, A. (2015) · Breast Care · doi:10.1159/000433622 · Cited by 100
Al‐Souhibani, N., Al‐Ahmadi, W., Hesketh, J. E., Blackshear, P. J., & Khabar, K. S. A. (2010) · Oncogene · doi:10.1038/onc.2010.168 · Cited by 98
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
Elster, N., Collins, D. M., Toomey, S., Crown, J. P., Eustace, A. J., & Hennessy, B. T. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3250-x · Cited by 97
Targeted therapies for ER+/HER2- metastatic breast cancer
Yamamoto‐Ibusuki, M., Arnedos, M., & André, F. (2015) · BMC Medicine · doi:10.1186/s12916-015-0369-5 · Cited by 95
Grunt, T. W., & Mariani, G. L. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313020008 · Cited by 93
Johnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92
Promising molecular targeted therapies in breast cancer
Munagala, R., Aqil, F., & Gupta, R. C. (2011) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.81497 · Cited by 92
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
Boyraz, B., Şendur, M. A. N., Aksoy, S., Babacan, T., Roach, E. C., Kızılarslanoğlu, M. C., Petekkaya, İ., & Altundağ, K. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.775113 · Cited by 91
Yang, F., Lyu, S., Dong, S., Liu, Y., Wang, O., & Zhang, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s97664 · Cited by 88
Chinchar, E., Makey, K. L., Gibson, J., Chen, F., Cole, S. A., MEGASON, G. C., Vijayakumar, S., Miele, L., & Gu, J. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-12 · Cited by 87
Dey, N., Williams, C. B., Leyland-Jones, B., & De, P. K. (2015) · PubMed · Cited by 79
Griseri, P., Bourcier, C., Hiéblot, C., Essafi‐Benkhadir, K., Chamorey, E., Touriol, C., & Pagès, G. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr390 · Cited by 77
Self-citationSTAT signaling in different breast cancer sub-types
Furth, P. A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.023 · Cited by 73
Rechallenging with anthracyclines and taxanes in metastatic breast cancer
Palmieri, C., Krell, J., James, C. R., Harper-Wynne, C. L., Misra, V., Cleator, S. J., & Miles, D. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.122 · Cited by 67
New approaches for improving outcomes in breast cancer in Europe
Leo, A. D., Curigliano, G., Dieras, V. C., Malorni, L., Sotiriou, C. P., Swanton, C., Thompson, A. M., Tutt, A. N. J., & Piccart, M. J. (2015) · The Breast · doi:10.1016/j.breast.2015.03.001 · Cited by 67
Iida, M., Brand, T. M., Starr, M. M., Huppert, E. J., Luthar, N., Bahrar, H., Coan, J. P., Pearson, H. E., Salgia, R., & Wheeler, D. L. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-242 · Cited by 65
Identifying and targeting tumor-initiating cells in the treatment of breast cancer
Wei, W., & Lewis, M. T. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0447 · Cited by 62
Duru, N., Candas, D., Jiang, G., & Li, J. J. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1494-1 · Cited by 61
Better Together: Targeted Combination Therapies in Breast Cancer
Zanardi, E., Bregni, G., de Braud, F., & Cosimo, S. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.029 · Cited by 57
Kaumaya, P. T. P., & Foy, K. C. (2012) · Future Oncology · doi:10.2217/fon.12.95 · Cited by 53
Translating neoadjuvant therapy into survival benefits: one size does not fit all
Mattos‐Arruda, L. D., Shen, R., Reis-Filho, J. S., & Cortés, J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.35 · Cited by 53
Kawalec, P., Łopuch, S., & Mikrut, A. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.10.006 · Cited by 52
Quantification of HER family receptors in breast cancer
Nuciforo, P. G., Radosevic‐Robin, N., Ng, T., & Scaltriti, M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0561-8 · Cited by 51
Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
Chan, A., Miles, D. W., & Pivot, X. B. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq122 · Cited by 44
Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer
Kerbel, R. S. (2009) · The Breast · doi:10.1016/s0960-9776(09)70271-1 · Cited by 42
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 41
Hatem, R., Botty, R. E., Château‐Joubert, S., Servely, J., Labiod, D., de Plater, L., Assayag, F., Coussy, F., Callens, C., Vacher, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10195 · Cited by 41
Clavarezza, M., Puntoni, M., Gennari, A., Paleari, L., Provinciali, N., D’Amico, M., & DeCensi, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1881 · Cited by 40
RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes
Weinberg, M. A. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000354 · Cited by 39
Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance
Li, S., Payne, S., Wang, F., Claus, P., Su, Z., Groth, J., Geradts, J., de Ridder, G., Álvarez, R., Marcom, P. K., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0590-3 · Cited by 37
Regulation of the mRNA half-life in breast cancer
Griseri, P., & Pagès, G. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.323 · Cited by 36
Self-citationGriseri, P., & Pagès, G. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0140 · Cited by 36
Self-citationDe, P. K., Miskimins, K. W., Dey, N., & Leyland-Jones, B. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.002 · Cited by 34
Kanaya, N., Somlo, G., Wu, J., Frankel, P. H., Kai, M., Liu, X., Wu, S. V., Nguyen, D. M., Chan, N., Hsieh, M.-Y., et al. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.05.001 · Cited by 34
Ito, Y., Tokudome, N., Sugihara, T., Takahashi, S., & Hatake, K. (2007) · Breast Cancer · doi:10.2325/jbcs.971 · Cited by 33
Azim, H. A., Kassem, L. M. H., Treilleux, I., Wang, Q., Enein, M. A. E., Anis, S. E., & Bachelot, T. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.01.001 · Cited by 32
Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.09.004 · Cited by 27
Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
Almstedt, K., & Schmidt, M. (2015) · Breast Care · doi:10.1159/000405017 · Cited by 22
Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model
Glaysher, S., Bolton, L. M., Johnson, P., Torrance, C. J., & Cree, I. A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-397 · Cited by 19
A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akın, S., Babacan, T., Sarici, F., & Altundağ, K. (2014) · PubMed · Cited by 19
Predictive Diagnostic Pathology in the Target Therapy Era in Breast Cancer
Marchiò, C., Balmativola, D., Castiglione, R., Annaratone, L., & Sapino, A. (2016) · Current Drug Targets · doi:10.2174/1389450116666150203121218 · Cited by 18
Injecting Hope--A Review of Breast Cancer Vaccines.
Mittendorf, E. A., & Peoples, G. E. (2016) · PubMed · Cited by 15
Hurrell, T., & Outhoff, K. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-97 · Cited by 14
Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer
Chamberlin, M. D., Bernhardt, E. B., & Miller, T. W. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25590 · Cited by 14
Cited by
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Projected estimates of cancer in Canada in 2020
Brenner, D. R., Weir, H. K., Demers, A. A., Ellison, L. F., Louzado, C., Shaw, A., Turner, D., Woods, R. R., & Smith, L. M. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191292 · Cited by 375
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Metadata
- Authors
- Masoud, V., & Pagès, G.
- Venue
- World Journal of Clinical Oncology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2017
- Volume
- 8
- Issue
- 2
- Pages
- 120
- ISSN
- 2218-4333 (ISSN-L)
- OpenAlex
- W2604622211
- Cited by
- 357
- References
- 116
- FWCI
- 19.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.